Cargando…
Convergence of pathway analysis and pattern recognition predicts sensitization to latest generation TRAIL therapeutics by IAP antagonism
Second generation TRAIL-based therapeutics, combined with sensitising co-treatments, have recently entered clinical trials. However, reliable response predictors for optimal patient selection are not yet available. Here, we demonstrate that a novel and translationally relevant hexavalent TRAIL recep...
Autores principales: | Vetma, Vesna, Guttà, Cristiano, Peters, Nathalie, Praetorius, Christian, Hutt, Meike, Seifert, Oliver, Meier, Friedegund, Kontermann, Roland, Kulms, Dagmar, Rehm, Markus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7370234/ https://www.ncbi.nlm.nih.gov/pubmed/32081986 http://dx.doi.org/10.1038/s41418-020-0512-5 |
Ejemplares similares
-
Sensitization of glioblastoma cells to TRAIL-induced apoptosis by IAP- and Bcl-2 antagonism
por: Lincoln, Frank A., et al.
Publicado: (2018) -
IgG-single-chain TRAIL fusion proteins for tumour therapy
por: Siegemund, Martin, et al.
Publicado: (2018) -
Examining the In Vitro Efficacy of the IAP Antagonist Birinapant as a Single Agent or in Combination With Dacarbazine to Induce Melanoma Cell Death
por: Vetma, Vesna, et al.
Publicado: (2017) -
Systemic network analysis identifies XIAP and IκBα as potential drug targets in TRAIL resistant BRAF mutated melanoma
por: Del Mistro, Greta, et al.
Publicado: (2018) -
Targeting scFv-Fc-scTRAIL fusion proteins to tumor cells
por: Hutt, Meike, et al.
Publicado: (2018)